APA (7th ed.) Citation

Pandit-Taskar, N., O'Donoghue, J. A., Ruan, S., Lyashchenko, S. K., Carrasquillo, J. A., Heller, G., . . . Morris, M. J. (2016). First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake. Journal of Nuclear Medicine, 57(12), 1858. https://doi.org/10.2967/jnumed.116.176206

Chicago Style (17th ed.) Citation

Pandit-Taskar, Neeta, et al. "First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake." Journal of Nuclear Medicine 57, no. 12 (2016): 1858. https://doi.org/10.2967/jnumed.116.176206.

MLA (9th ed.) Citation

Pandit-Taskar, Neeta, et al. "First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake." Journal of Nuclear Medicine, vol. 57, no. 12, 2016, p. 1858, https://doi.org/10.2967/jnumed.116.176206.